TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
The Pharma Data
JULY 11, 2021
TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. The reagents used in the aPTT laboratory test initiate intrinsic coagulation through the activation of plasma kallikrein in the contact system. No dedicated drug-drug interaction studies have been conducted.
52 
Let's personalize your content